CRDF · Cardiff Oncology, Inc. · Financials
$1.21
+0.00 (+0.00%)
At close · Sep 11
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has performed an analysis and concluded that there exists a substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$94.13M
Shares
77.80M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$593K
-13.2%
FY2025
Net Income
-$45.85M
-0.9%
FY2025
Gross Margin
100%
+157.9pp
FY2019
Operating Margin
-8256.32%
-1133.2pp
FY2025
Diluted EPS
-$0.69
+27.4%
FY2025
Operating Cash Flow
-$37.92M
-0.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $508K | $593K | $683K | $488K | $386K | $359K | $365.99K | $244.63K | $378.33K | $505.4K | $381.07K | $312.81K | $280.18K | $259.25K | $450.4K | $257.7K | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | -$1.38M | -$1.47M | -$831.02K | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | $0 | $597.46K | $1.81M | $1.73M | $629.19K | $15.44K | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | $244.63K | -$219.13K | -$1.31M | -$1.35M | -$316.38K | $264.74K | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | 100% | -57.92% | -258.41% | -354.12% | -101.14% | 94.49% | — | — | — | — | — | — | |
| $25.95M | $35.33M | $36.85M | $32.86M | $27.1M | $17.4M | $11.24M | $11.16M | $8.16M | $7.88M | $15.01M | $10.59M | $6.66M | $3.95M | $1.92M | $910.69K | — | — | — | |
| — | — | — | — | — | — | — | — | — | $2.74M | $11.52M | $6.44M | $2.73M | $1.53M | $506.54K | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $11.5M | $11.48M | $7.92M | $5.81M | $5.47M | $2.87M | $2.32M | — | — | — | |
| $16.82M | $14.22M | $12.48M | $13.04M | $13.18M | $11.84M | $8.22M | $5.76M | $8.01M | $14.23M | — | — | — | $7M | $3.38M | $2.32M | — | — | — | |
| $351K | $364K | $404K | $398K | $236K | $451K | $466K | $494.23K | $859.49K | $1.25M | $1.07M | $378.71K | $234.81K | $130.52K | $41.84K | $10.29K | — | — | — | |
| — | — | — | — | — | — | — | $0 | $664.69K | $2.17M | $790.44K | $0 | $0 | — | — | — | — | — | — | |
| $42.77M | $49.55M | $49.33M | $45.9M | $40.29M | $29.21M | $19.45M | $16.92M | $17.43M | $26.1M | $40.53M | $25.59M | $15.23M | $10.95M | $5.3M | — | — | — | — | |
| $13.56M | — | — | — | — | — | — | — | — | — | — | — | — | $10.95M | $5.3M | $3.23M | — | — | — | |
| -$42.27M | -$48.96M | -$48.65M | -$45.41M | -$39.9M | -$28.86M | -$19.09M | -$16.68M | -$17.05M | -$25.6M | -$40.15M | -$25.27M | -$14.95M | -$10.69M | -$4.85M | -$2.98M | — | — | — | |
| — | -8256.32% | -7123.13% | -9305.74% | -10337.31% | -8037.6% | -5214.85% | -6817.79% | -4507.61% | -5064.42% | -10534.91% | -8079.5% | -5334.17% | -4123.71% | -1076.62% | -1155.16% | — | — | — | |
| -$41.92M | -$48.6M | -$48.25M | -$45.01M | -$39.67M | -$28.4M | -$18.62M | -$16.18M | -$16.19M | -$24.35M | -$39.08M | -$24.89M | -$14.71M | -$10.56M | -$4.81M | -$2.97M | — | — | — | |
| — | — | — | — | — | $0 | $2000 | $0 | $25.41K | $1.03M | $1.67M | $1.53M | $843.26K | $17.01K | — | $56.64K | — | — | — | |
| $2.22M | $3.1M | $3.26M | $4.07M | $1.58M | $264K | $90K | $234.17K | $219.43K | $147.88K | $298.83K | — | — | — | — | — | — | — | — | |
| $2.22M | $3.11M | $3.22M | $3.97M | $1.2M | $564K | -$221K | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$45.85M | -$45.43M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | |
| -$40.05M | -$45.85M | -$45.43M | -$41.44M | -$38.7M | -$28.29M | -$19.31M | -$16.41M | -$16.46M | -$24.91M | -$39.2M | -$27.47M | -$14.33M | -$11.81M | -$11.57M | -$2.24M | -$5.45M | -$2.48M | -$5.17M | |
| — | -7732.04% | -6651.68% | -8492.01% | -10026.94% | -7880.5% | -5275.24% | -6709.74% | -4351.07% | -4928.09% | -10287.75% | -8781.98% | -5112.99% | -4555.88% | -2567.91% | -868.94% | — | — | — | |
| -$40.08M | -$45.88M | -$45.46M | -$41.47M | -$38.73M | -$28.32M | -$22.6M | -$16.71M | -$19.25M | -$24.93M | -$39.23M | -$27.5M | -$14.35M | -$11.84M | -$11.6M | -$2.28M | — | — | — | |
| -$40.13M | -$45.84M | -$45.33M | -$41.11M | -$38.96M | -$28.43M | -$19.31M | — | -$19.25M | -$24.92M | -$39.24M | — | -$14.35M | — | — | — | — | — | — | |
| USD/shares | -$0.60 | -$0.69 | -$0.95 | -$0.93 | -$0.89 | -$0.73 | -$1.08 | — | -$8.26 | -$51.76 | -$1.30 | -$1.05 | -$0.76 | -$0.70 | -$0.89 | — | — | — | — |
| USD/shares | -$0.60 | -$0.69 | -$0.95 | -$0.93 | -$0.89 | -$0.73 | -$1.08 | — | -$8.26 | -$51.76 | -$1.37 | -$1.21 | -$0.88 | -$0.70 | -$0.89 | — | — | — | — |
| shares | — | 66.84M | 47.65M | 44.68M | 43.6M | 39.03M | 20.88M | 5.97M | 2.33M | 481.67K | 30.17M | 26.2M | 18.9M | 16.98M | 13.07M | 9.71M | — | — | — |
| shares | — | 66.84M | 47.65M | 44.68M | 43.6M | 39.03M | 20.88M | 5.97M | 2.33M | 481.67K | 30.28M | 26.45M | 19.07M | 16.98M | 13.07M | 9.71M | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.48×
EV/EBIT
—
Peer median 10.68×
P/E (TTM)
—
Peer median 8.07×
Peer medians compare against the 308 similar-size Biotechnology companies (of 536 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2020 | FY2019 |
|---|---|---|
| Royalty | $365,993 | $243,137 |